Xeris Biopharma Holdings Inc
WKN: A3C4ZC / ISIN: US98422E1038Strongbrigde Biopharma 200 Prozent Potential?
11.11.15 20:58
#1
Balu4u
Strongbrigde Biopharma 200 Prozent Potential?
Ausgehend vom aktuell Kurs zum KZ von 21USD
http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835
Pipeline
http://www.strongbridgebio.com/pipeline/
http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835
Pipeline
http://www.strongbridgebio.com/pipeline/
20 Postings ausgeblendet.
07.11.19 16:40
#23
Balu4u
Zahlen
https://www.zacks.com/stock/news/608278/...=CS-ZC-FT-tale_of_the_tape|yseop_template_4-608278
17.09.20 18:23
#31
Balu4u
raises $25M by public offering
https://seekingalpha.com/news/...eed_news_all&utm_medium=referral
30.12.21 23:23
#35
Balu4u
Geschenk zum Jahresende - after hours + 28 Prozent
https://seekingalpha.com/news/...eed_news_all&utm_medium=referral
https://www.nasdaq.com/de/market-activity/stocks/xers/real-time
https://seekingalpha.com/news/...eed_news_all&utm_medium=referral
https://www.nasdaq.com/de/market-activity/stocks/xers/real-time
03.01.22 23:51
#36
Balu4u
Günstig!?
Now what
Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.
Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.
During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.
At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.
https://www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/
Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.
Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.
During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.
At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.
https://www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/
16.02.22 17:20
#38
Balu4u
Stimmt jetzt die Richtung?
20 Prozent in einem Monat ist aktuell für einen Biotechtitel nicht schlecht, zumindest wenn es gen Norden geht! Aber nachhaltig sollten die 2,90 / 3 Dollar noch aus dem Weg geräumt werden...
https://www.nasdaq.com/de/market-activity/stocks/xers/real-time
https://www.nasdaq.com/de/market-activity/stocks/xers/real-time
05.01.24 10:43
#39
Balu4u
darum geht es hoch
https://www.nasdaq.com/articles/...-04-2024%3A-sem-xers-rxrx-omga-nvo